Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FluMist, AstraZeneca and influenza vaccine
AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, and this rate is only expected to increase marginally over the coming years.
FDA approves AstraZeneca FluMist ‘flu vaccine for self-administration
Since its initial US approval in 2003, 200 million doses of FluMist have been distributed globally. The new self-administration option will soon allow individuals aged 18 years an
AstraZeneca's FluMist nasal spray vaccine approved for self-administration
The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered by a caregiver. The approval means that FluMist, which is made by the drugmaker's MedImmine division,
The Motley Fool UK
1d
As AstraZeneca’s share price drops 13% should I buy on the dip?
And on 20 September, the US FDA approved
AstraZeneca
’s
FluMist
influenza nasal spray vaccine for self-administration.
KSBW The Central Coast
6d
FDA approves first flu vaccine that can be self-administered at home
AstraZeneca
says
FluMist
has been shown to be as effective as other flu vaccines.When the FDA announced last year that it was reviewing the possibility of a self-administered flu vaccine ...
CNET
3d
An At-Home Flu Vaccine? It'll Be Available Next Year
FluMist
won't be available until next year, according to the website for
FluMist
, which is owned by
AstraZeneca
. Once ...
4d
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Food and Drug Administration
United States
Influenza vaccine
FDA
Feedback